On March 22, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) released the annual report of 2021. During the reporting period, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) achieved an operating revenue of 39.005 billion yuan, an increase of 28.70% year-on-year; The net profit attributable to shareholders of listed companies was 4.735 billion yuan, a year-on-year increase of 29.28%; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 3.277 billion yuan, a year-on-year increase of 20.60%; The net cash flow from operating activities was 3.949 billion yuan, a year-on-year increase of 53.07%.
Under the guidance of the “4in” (innovation, internationalization, integration and intelligent Intelligence) strategy, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) continue to adhere to the business philosophy of “continuous innovation and enjoy health”, continue to promote innovation transformation, comprehensively speed up the international layout, strengthen the integration of R & D, supply chain, production and commercialization systems, and promote the improvement of business quality and operation efficiency, Achieve steady growth in performance.
Specifically, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) with innovative R & D as the core driving factor, through independent R & D, cooperative development, licensing and deep incubation, build and form small molecule innovative drugs, antibody drugs and cell therapy technology platforms around key diseases such as tumor and immune regulation, metabolism and digestive system, central nervous system, and actively explore RNA, oncolytic virus, gene therapy Targeted protein degradation and other cutting-edge technical fields to improve innovation ability. At the same time, through the integrated management of innovative R & D projects by the global R & D center, promote the development and implementation of innovative technologies and products.
R & D investment increased by 2.47 billion yuan in the whole year, with a year-on-year increase of 4.8 in the report period; Among them, the R & D cost was 3.834 billion yuan, a year-on-year increase of 1.039 billion yuan or 37.17%. Among them, the R & D investment in pharmaceutical business was 4.486 billion yuan, a year-on-year increase of 22.23%, and the R & D investment in pharmaceutical business accounted for 15.52% of the revenue of pharmaceutical business; Among them, the R & D expenses were 3.359 billion yuan, a year-on-year increase of 891 million yuan, an increase of 36.10%, accounting for 11.62% of the revenue of pharmaceutical business.
By the end of the reporting period, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) R & D personnel had more than 2800, of which more than 1500 had master’s degrees or above, accounting for about 7.85% of the total number of employees in the group. By the end of the reporting period, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) were developing more than 240 new drugs, biological analogues, generic drugs, consistency evaluation and other projects.
